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Abstract
Background: Glucose-6-Phosphate dehydrogenase (G6PD) is a key enzyme of the pentose monophosphate pathway, 
and its deficiency is the most common inherited enzymopathy worldwide. G6PD deficiency is common among Iraqis, 
including those of the Kurdish ethnic group, however no study of significance has ever addressed the molecular basis 
of this disorder in this population. The aim of this study is to determine the prevalence of this enzymopathy and its 
molecular basis among Iraqi Kurds.
Methods: A total of 580 healthy male Kurdish Iraqis randomly selected from a main regional premarital screening 
center in Northern Iraq were screened for G6PD deficiency using methemoglobin reduction test. The results were 
confirmed by quantitative enzyme assay for the cases that showed G6PD deficiency. DNA analysis was performed on 
115 G6PD deficient subjects, 50 from the premarital screening group and 65 unrelated Kurdish male patients with 
documented acute hemolytic episodes due to G6PD deficiency. Analysis was performed using polymerase chain 
reaction/restriction fragment length polymorphism for five deficient molecular variants, namely G6PD Mediterranean 
(563 C→T), G6PD Chatham (1003 G→A), G6PD A- (202 G→A), G6PD Aures (143 T→C) and G6PD Cosenza (1376 G→C), 
as well as the silent 1311 (C→T) mutation.
Results: Among 580 random Iraqi male Kurds, 63 (10.9%) had documented G6PD deficiency. Molecular studies 
performed on a total of 115 G6PD deficient males revealed that 101 (87.8%) had the G6PD Mediterranean variant and 
10 (8.7%) had the G6PD Chatham variant. No cases of G6PD A-, G6PD Aures or G6PD Cosenza were identified, leaving 4 
cases (3.5%) uncharacterized. Further molecular screening revealed that the silent mutation 1311 was present in 93/95 
of the Mediterranean and 1/10 of the Chatham cases.
Conclusions: The current study revealed a high prevalence of G6PD deficiency among Iraqi Kurdish population of 
Northern Iraq with most cases being due to the G6PD Mediterranean and Chatham variants. These results are similar to 
those reported from neighboring Iran and Turkey and to lesser extent other Mediterranean countries.
Background
Glucose-6-Phosphate Dehydrogenase (G6PD) is a key
enzyme in the pentose monophosphate pathway and pro-
vides the NADPH essential for a number of biosynthetic
and detoxifying reactions. The gene encoding G6PD is
located at Xq28, and its deficiency is the most common
enzymopathy in humans. As an X-linked recessive trait, it
is predominantly a disease of males affecting an esti-
mated 400 million people worldwide [1]. This deficiency
is associated with a variable spectrum of clinical manifes-
tations including the following: favism, neonatal jaundice,
drug induced hemolysis, chronic non-spherocytic hemo-
lytic anemia and infection induced hemolysis [2]. The lat-
ter variability is suggestive of biochemical heterogeneity.
More than 400 G6PD biochemical variants have already
been described [1]. More recently cloning and sequenc-
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ing of the G6PD gene allowed researchers to characterize
more than 140 molecularly distinct variants [3].
G6PD deficiency is prevalent in many countries in the
Eastern Mediterranean Region including Iraq [4-8]. Some
studies have addressed the prevalence of G6PD defi-
ciency in central and southern Iraq [8-10], but none are
available from the northern region. The population of
n o r t h e r n  I r a q  c o n s i s t s  o f  a  m a j o r i t y  o f  e t h n i c  K u r d s
unlike other parts of the country where Arabs predomi-
nate. Kurds constitute the fourth largest ethnic group in
the Eastern Mediterranean after Arabs, Persians and
Turks. They inhabit a region called Kurdistan covering
adjacent parts of Iraq, Iran, Turkey and Syria. The origin
of Kurds has been a subject of speculation. Based on cul-
tural and linguistic evidence, some historians believe that
Kurds are predominantly an Indo-European ethnic group
who had migrated and settled in Iran, Iraq and Turkey
more than 2000 years ago [11]. However the region has
been inhabited by earlier populations since prehistoric
times and has been ruled throughout its long history by
several major powers including the Assyrians, Persians,
Greeks, Romans, Arabs and Turks [12]. All these factors
may have contributed to the genetic makeup of the pres-
ent-day Kurds.
Genetic studies including those of inherited blood dis-
orders are very scarce on Kurds, and such studies may
help explain the origin and spread of these disorders and
may also help shed some light on the history of this ethnic
group. No study of significance has addressed the fre-
quency of G6PD deficiency in the Kurdish Iraqi popula-
tion, and none has defined the deficient molecular
variants among any group of Iraqis, despite the fact that
favism is a commonly encountered health problem
throughout the country.
This study aims to: 1) determine the prevalence of
G6PD deficiency in a random sample of healthy Iraqi
Kurdish males attending a regional premarital screening
center, and 2) define the molecular basis of G6PD defi-
ciency among a sample of G6PD deficient males in the
same region.
Methods
The study was conducted in the period between July and
December 2009. The subjects enrolled were males
attending the Central laboratory in Dohuk, northern Iraq
for routine premarital health screening. This laboratory
serves a population of around one million of mainly eth-
nic Kurds, and is the only facility in this province that is
authorized to provide government mandated premarital
investigations. The latter currently include investigation
for blood groups, HBsAg, HIV and carrier screening for
specific hemoglobinopathies. The center receives on
average around 30-40 couples per day. The study subjects
were the male partners of the first 10 couples attending
the center on every other working day throughout the
study period.
A 6 ml blood sample was collected in K2-EDTA tubes
from each enrollee. The sample was used to screen for
G6PD deficiency by methemoglobin reduction test [13].
All those identified as G6PD deficient and an equal num-
ber of age matched non-deficient individuals were further
tested by quantitative enzyme assay according to the
manufacturer instructions (Biolabo - France). Confirmed
deficient individuals were recalled for molecular testing.
Additionally, 65 unrelated male patients who had docu-
mented hemolytic episodes associated with G6PD defi-
ciency, were also recalled and had their G6PD deficient
status reaffirmed by quantitative enzyme assay.
All G6PD deficient individuals had their DNA
extracted by a phenol-chloroform based method [14].
The extracted DNA was screened sequentially for five
G6PD deficient mutations namely G6PD Mediterranean
(563 C→T), G6PD Chatham (1003 G→A), G6PD
Cosenza (1376 G→C), G6PD Aures (143 T→C), G6PD
A- (202 G→A) and for silent (1311 C→T) mutation using
polymerase chain reaction/restriction fragment length
polymorphism (PCR/RFLP) based method. These five
deficient variants were selected for screening since they
were the five most common variants reported in Iraq's
surrounding countries [5,6,15-19]. The primers, ampli-
fied exons and restriction enzymes used for each of these
reactions are outlined in table 1. Further procedure
details were performed as previously reported [20-23].
Informed consent was taken form all enrollees or their
guardians and the study was approved by the appropriate
ethical committee at the Dohuk college of Medicine, Iraq.
Statistical analysis utilized the Mann Whitney U test
and Chi Squared test wherever appropriate. A p < 0.05
was considered significant.
Results
Among 580 Kurdish male premarital screening subjects,
63 individuals (10.9%) were found to be G6PD deficient
by methemoglobin reduction test with all subsequently
being confirmed as deficient by quantitative enzyme
assay. Table 2 shows the G6PD enzyme levels in the defi-
cient individuals as well as an equal number of age
matched G6PD non-deficient males.
Among the 63 G6PD deficient males detected, 50
responded to a recall for molecular characterization.
Additionally, 65 previously diagnosed males with G6PD
deficiency associated documented hemolytic episodes
also underwent quantitative enzyme assays (table 2) and
molecular investigation. Molecular characterization of
these 115 G6PD deficient individuals revealed that the
G6PD Mediterranean (563 C→T) was the most common
and was detected in 101 of 115 individuals (87.8%), fol-
lowed by G6PD Chatham (1003 G→A) that was detectedAl-Allawi et al. BMC Blood Disorders 2010, 10:6
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in 10 (8.7%). No cases with G6PD A-, Aures or Cosenza
were identified. This left four cases (3.5%) uncharacter-
ized. There were no significant differences in the distri-
bution of molecular G6PD variants among G6PD
deficient individuals detected by screening and those
with previously documented hemolytic episodes (table 3).
On the other hand, the mean enzyme concentration of
subjects with Mediterranean variant was significantly
lower at 0.5798 + 0.357 IU/g Hb than subjects with the
Chatham variant at 0.846 + 0.3299 IU/g Hb, P = 0.029.
The silent mutation (1311 C→T) was documented in
93/95 (97.8%) of the Mediterranean deficient variants, in
1/10 of the Chatham cases and in one of the three
uncharacterized variants.
Discussion
G6PD deficiency has long been recognized as a common
inherited hematological disorder in Iraqis including
Kurds [7,8]. Kurds make up about 20% of the population
of Iraq, and they live in Northern and Northeastern Iraq.
The area covered by the current study in northern Iraq
lies at the center of the Kurdish inhabited areas of the
Eastern Mediterranean Region.
Earlier limited studies on G6PD deficiency among Iraqi
Kurdish males living in Baghdad (at the center of the
country) have reported frequencies of 7.6-8.8% [7,9],
which is slightly lower than the frequency of 10.9% as
documented in this study. The latter rate is also higher
than rates reported from the neighboring Kurdish popu-
lation of western Iran [15], but is remarkably less than
reports from Kurdish Jews, who have one of the highest
rates worldwide of up to 58% [24]. Previous studies from
other parts of Iraq revealed variable results from Baghdad
(6.1-12.4%) at the center of country and 15.3% from Basra
at the extreme south [7-10]. As outlined in Table 4, poly-
morphic frequencies of G6PD deficiency were reported
throughout the Eastern Mediterranean Region ranging
from 2% in Lebanon to 39.8% in Eastern Saudi Arabia [4-
10,15,25,26]. The polymorphic frequency of G6PD defi-
ciency in Iraq and in the Eastern Mediterranean Region
may be linked to selective advantage against malaria in
these previously highly endemic areas [1,27]. Northern
Iraq was highly endemic in Malaria up to the fifties and
sixties of the last century when control programs spon-
sored by the WHO managed to control the disease, but it
remerged in the nineties particularly in the area covered
by this study [28-30].
The predominance of the Mediterranean mutation (563
C→T) as demonstrated in the current study, has been
documented by many studies from the Eastern Mediter-
ranean countries, where it constitutes 54 to 91% of G6PD
variants identified (table 5) [5,6,15-19]. Our figures are
comparable to those reported in Kurds from neighboring
western Iran or from Kurdish Jews of 80-97% [15,24]. It is
Table 1: The primer sequences, exons amplified and the restriction enzymes used in the PCR/RFLP procedures to detect 
five G6PD deficient mutations and the silent one 
Variant Primers Exon amplified Restriction Enzyme
Mediterranean
(563 CTT)
5'GGT GAG GCT CCT GAG TAC CA 3' VI MboII
5'AGC TGT GAT CCT CAC TCC CC 3'
Chatham
(1003 GTA)
5'CAA GGA GCC CAT TCT CTC CCT T 3' IX BstXI
5'TTC TCC ACA TAG AGG AGG ACG GCT GCC AAA GT3'
A-
(202 GTA)
5'CGT GTC CCC AGC CAC TTC TA 3' III-V NlaIII
5' CAC GCT CAT AGA GTG GTG GG 3'
Cosenza
(1376 GTC)
5'GCA GCC AGT GGG ATC AGC AAG 3'
5' GGC AAG GAG GGT GGC CGT GG 3'
XI-XIII Bsu361
Aures
(143 TTC)
5' CAG CCA CTT CTA ACC ACA CAC Ct 3'
5' CCG AAG TTG GCC ATG CTG GG 3'
III Mbo I
Silent
(1311 CTT)
5' TGT TCT TTC AAC CCC GAG GAG T 3'
5' AAG ACG TCC AGG ATG AGG TGA TC 3'
Part X-XI Bcl IAl-Allawi et al. BMC Blood Disorders 2010, 10:6
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important to note that based on biochemical character-
ization, the Mediterranean variant has been presumably
detected in 58.6% of 31 G6PD deficient males from an
earlier study in Baghdad [9]. However, the small number
of biochemically characterized deficient variants in the
latter study and the fact that biochemical phenotypes are
not absolutely related to particular molecular variants
[31] would limit the feasibility of making reliable compar-
isons with the current study. The ethnic background of
Baghdad's population is different from that of northern
Iraq, thus the presumed lower frequency of the Mediter-
ranean mutation maybe actual but would require molec-
ular studies to be verified. The G6PD Mediterranean
variant is also the predominant mutation among other
Mediterranean countries like Italy and Greece as well as
in the Indian subcontinent, but it is virtually non-existent
in Central and South Africa and it shows a decreasing fre-
quency as we move to the east from India (table 5) [32-
38]. As with other Mediterranean and Middle Eastern
countries, the large majority of those with G6PD Medi-
terranean carry the silent 1311 C→T mutation, and only
2 of the 95 cases tested in this study were non-carriers,
the latter maybe due an intragenic recombinant event or
population admixture [15,39,40]. Tishkoff and coworkers
after studying some highly polymorphic microsatellites
and RFLPs in and around the G6PD gene proposed that
the Mediterranean mutation is of rather recent origin,
originating somewhere in the Mediterranean basin
within the past 1600 to 6640 years. Thereafter, it was
spread to Middle East and North Africa by extensive
trade routes and colonization by the Greeks in the first
millennium BC. The pattern of distribution of the Medi-
terranean mutation (with the silent 1311 T mutation)
makes it quite conceivable that it may have spread
through the army of Alexander the Great who conquered
the Middle East and North Africa and went as far east as
India [41]. The Kurdistan region was a path which he
used to pursue his conquests to Persia and beyond [12].
The mutation, thereafter, may have been selected for by
malaria already highly endemic in these fertile agricul-
tural lands, particularly around 500BC and thereafter. It is
important to note that the Mediterranean mutation has
also been reported predominantly without the silent
mutation (i.e. with 1311 C) in the Indian subcontinent
and southern Italy, which led many investigators to sug-
gest two independent origins of the Mediterranean muta-
tion [34,39,42].
Table 2: Mean and standard deviation (SD) of G6PD enzyme concentrations (IU/g Hb) in the two G6PD deficient groups 
and healthy non-deficient males
Category No G6PD Enzyme concentration
(IU/g Hb)
Mean SD
Group A: G6PD deficient healthy individuals detected by premarital screening 63 0.6670 0.445
Group B: G6PD deficient patients with history of hemolytic episode(s). 65 0.6385 0.443
G6PD non-deficient healthy individuals 63 12.206 0.827
No significant difference were observed in the enzyme concentration between the two deficient groups (p = 0.744)
Table 3: The distribution of the G6PD deficient molecular variants in asymptomatic individuals detected by premarital 
screening and in patients with history of hemolytic episodes in the current study
Number of cases (%)
Category (no.) Mediterranean Chatham Uncharacterized
G6PD Deficient healthy individuals (50) 45 (90) 3 (6) 2 (4)
G6PD Deficient patients (65) 56 (86.2) 7 (10.8) 2 (3.1)
Total (115) 101(87.8) 10 (8.7) 4 (3.5)Al-Allawi et al. BMC Blood Disorders 2010, 10:6
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The second most frequent variant detected by the cur-
rent study is G6PD Chatham (1003, G→A) seen in 8.7%
of deficient individuals. G6PD Chatham, although first
described in a patient of Asian Indian origin, is now rec-
ognized as one of the common variants worldwide [15].
Table 5 outlines the frequencies of the latter mutation in
various Eastern Mediterranean countries and shows
rather comparable figures among Iranian Kurds in west-
ern Iran [15]. However, figures for its frequency vary in
other parts of the latter country reaching 27% in North-
ern Iran [16,17]. This variant may have been introduced
to northern Iraq through gene flow from neighboring
Iran.
G6PD Cosenza (1376 G→C) was first described in
Southern Italy [43] and has been reported in variable fre-
quencies by some Iranian studies including the one on
Kurds [15,16]. However, this variant was not detected in
any deficient individual in the current study. G6PD Aures
(143 T→C) was first described in Algeria [22]. Since then
it has also been reported in variable frequencies in Jor-
dan, Kuwait and western Saudi Arabia [18,19,44]. How-
ever it was not reported among Iranian Kurds or in
neighboring Turkey [15,26] as is the case in the current
study.
The African A-variant (202 G→A) was not detected
among our sample. This is in contrast to an earlier report
from central Iraq where it was reported in 4.3% of G6PD
deficient subjects [9] and in some Arab Eastern Mediter-
ranean countries where rates between 5.8-14.2% were
given (table 5). However, and similar to the current study,
absence of the variant has also been described in reports
on Iranian Kurds and Northern Iranians [15,16]. Absence
of the variant in these areas is most likely related to the
fact that the Kurdish inhabited areas of Iraq and neigh-
bouring Iran were, unlike Arabia, a much less likely desti-
nation of African gene flow prior to or during the reign of
the prosperous Islamic empire.
Table 4: Prevalence rates of G6PD deficiency in Iraq and some of the surrounding countries in Eastern Mediterranean 
Region
Country Prevalence (%) Ref
Iraq: Central (Baghdad) 6.1-12.3 [7-9]
Iraq: Southern (Basra) 15.3 [10]
Iraq: Northern (Kurds) 10.9 Current
Iran: Western (Kurds) 5.3 [15]
Jordan 3.6 [4]
Kuwait 5.5 [4]
Saudi Arabia 1-39.8 [25,45,46]
Syria 3.0 [4]
Turkey 0.5-20 [26]
Bahrain 18 [47]
Egypt 5.9 [48]
Lebanon 2.1 [4]
Oman 2-29 [49]
United Arab Emirates 11 [50]Al-Allawi et al. BMC Blood Disorders 2010, 10:6
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Conclusion
This study has documented that the frequency of G6PD
deficiency among the predominantly Kurdish population
in Northern Iraq is 10.9%, which is higher than that
reported from the neighboring Iranian Kurdish popula-
tion. The study which is the first molecular study on
G6PD deficient variants from Iraq documented that
G6PD Mediterranean and Chatham constitute the large
majority of the deficient variants which is similar to find-
ings reported in surrounding populations. Further studies
including larger number of patients, more diverse ethnic
backgrounds and including screening for other deficient
variants and DNA sequencing are needed to give a more
comprehensive view of G6PD variants in Iraqis.
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